Glišić, Sanja

Link to this page

Authority KeyName Variants
orcid::0000-0001-5691-1055
  • Glišić, Sanja (50)
Projects
Application of the EIIP/ISM bioinformatics platform in discovery of novel therapeutic targets and potential therapeutic molecules An integral study to identify the regional genetic and environmental risk factors for the common noncommunicable diseases in the human population of Serbia - INGEMA_S
Synthesis, Quantitative Structure and Activity Relationship, Physico-Chemical Characterisation and Analysis of Pharmacologically Active Substances Molecular determinants for tumor marker design
Basileus program Basileus S Program, Slovenian Research Agency program [P4-0053]
COST Action "Targeted chemotherapy towards diseases caused by endoparasites" (CM1307) COST Action Understanding Movement and Mechanism in Molecular Machines (CM1306)
ERA.Net RUS plus joint program grant [RUS_ST2017-309] Estonian Ministry for Education and Research [IUT34-14], EU COST Action [CM1307]
European Commission [TRIoH LSHG-CT-2003-503480] European Cooperation in Science and Technology (COST)
European COST Action (GLISTEN) [CM1207], Chiesi Foundation Fundacao para a Ciencia e a Tecnologia FCT (IF/01507/2015)
Fundacao para a Ciencia e a Tecnologia (PD/00133/2012) Fundacao para a Ciencia e a Tecnologia (PD/BD/113985/2015)
Fundacao para a Ciencia e a Tecnologia (PD/BD/128213/2016) Haridus-ja Teadusministeerium [Grant IUT34-14]
TRANSPLANT - Trans-national Infrastructure for Plant Genomic Science MAESTRA - Learning from Massive, Incompletely annotated, and Structured Data
Phylogenetic anaysis and molecular evolution of highly variable viruses: coinfections, host-pathogene interactions Identification of predictive molecular markers for cancer progression, response to therapy and disease outcome
Research and verification of the multidisciplinary forensic methods in Italian National Research Programme on AIDS 40H26
Ministry of Foreign Affairs, Luxembourg Ministry of Higher Education, Science and Technology of the Republic of Slovenia (P1-0012)
Ministry of Science and Technological Development of Serbia [143001] Ministry of Science and Technological Development of the Republic of Serbia [143001]
Ministry of Science and Technological Development of the Republic of Serbia [143001], COST Action [B28] Ministry of Science of the Republic of Serbia [143001]

Author's Bibliography

In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine

Matejin, Stanislava; Bukreyeva, Natalya; Radošević, Draginja; Senćanski, Milan V.; Mantlo, Emily; Veljković, Veljko; Glišić, Sanja; Paessler, Slobodan

(2020)

TY  - JOUR
AU  - Matejin, Stanislava
AU  - Bukreyeva, Natalya
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Mantlo, Emily
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Paessler, Slobodan
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9036
AB  - Background: Due to the limitations of current antiviral therapies because of drug resistance and the emergence of new circulating viral strains, novel effective antivirals are urgently needed. Results of the previous drug repurposing by virtual screening of DrugBank revealed the anticholinergic drug cycrimine as a possible inhibitor of the influenza virus infection. Methods: In this study we examined the potential antiviral activity of cycrimine in vitro. Results: The experimental results showed the anti-influenza activity of cycrimine against two different influenza A subtypes in cell culture. Conclusions: The findings of this study suggest cycrimine as a potential therapeutic agent for influenza. ©2019 International Medical Press.
T2  - Antiviral Therapy
T1  - In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine
VL  - 24
IS  - 8
SP  - 589
EP  - 593
DO  - 10.3851/IMP3348
ER  - 
@article{
author = "Matejin, Stanislava and Bukreyeva, Natalya and Radošević, Draginja and Senćanski, Milan V. and Mantlo, Emily and Veljković, Veljko and Glišić, Sanja and Paessler, Slobodan",
year = "2020",
url = "https://vinar.vin.bg.ac.rs/handle/123456789/9036",
abstract = "Background: Due to the limitations of current antiviral therapies because of drug resistance and the emergence of new circulating viral strains, novel effective antivirals are urgently needed. Results of the previous drug repurposing by virtual screening of DrugBank revealed the anticholinergic drug cycrimine as a possible inhibitor of the influenza virus infection. Methods: In this study we examined the potential antiviral activity of cycrimine in vitro. Results: The experimental results showed the anti-influenza activity of cycrimine against two different influenza A subtypes in cell culture. Conclusions: The findings of this study suggest cycrimine as a potential therapeutic agent for influenza. ©2019 International Medical Press.",
journal = "Antiviral Therapy",
title = "In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine",
volume = "24",
number = "8",
pages = "589-593",
doi = "10.3851/IMP3348"
}
Matejin, S., Bukreyeva, N., Radošević, D., Senćanski, M. V., Mantlo, E., Veljković, V., Glišić, S.,& Paessler, S. (2020). In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine.
Antiviral Therapy, 24(8), 589-593.
https://doi.org/10.3851/IMP3348
Matejin S, Bukreyeva N, Radošević D, Senćanski MV, Mantlo E, Veljković V, Glišić S, Paessler S. In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine. Antiviral Therapy. 2020;24(8):589-593
Matejin Stanislava, Bukreyeva Natalya, Radošević Draginja, Senćanski Milan V., Mantlo Emily, Veljković Veljko, Glišić Sanja, Paessler Slobodan, "In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine" Antiviral Therapy, 24, no. 8 (2020):589-593,
https://doi.org/10.3851/IMP3348 .

Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors

Radošević, Draginja; Senćanski, Milan V.; Perović, Vladimir R.; Veljković, Nevena V.; Prljić, Jelena; Veljković, Veljko; Mantlo, Emily; Bukreyeva, Natalya; Paessler, Slobodan; Glišić, Sanja

(2019)

TY  - JOUR
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
AU  - Mantlo, Emily
AU  - Bukreyeva, Natalya
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
PY  - 2019
UR  - https://www.frontiersin.org/article/10.3389/fcimb.2019.00067/full
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8163
AB  - Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.
T2  - Frontiers in Cellular and Infection Microbiology
T1  - Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors
VL  - 9
IS  - MAR
DO  - 10.3389/fcimb.2019.00067
ER  - 
@article{
author = "Radošević, Draginja and Senćanski, Milan V. and Perović, Vladimir R. and Veljković, Nevena V. and Prljić, Jelena and Veljković, Veljko and Mantlo, Emily and Bukreyeva, Natalya and Paessler, Slobodan and Glišić, Sanja",
year = "2019",
url = "https://www.frontiersin.org/article/10.3389/fcimb.2019.00067/full, http://vinar.vin.bg.ac.rs/handle/123456789/8163",
abstract = "Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.",
journal = "Frontiers in Cellular and Infection Microbiology",
title = "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors",
volume = "9",
number = "MAR",
doi = "10.3389/fcimb.2019.00067"
}
Radošević, D., Senćanski, M. V., Perović, V. R., Veljković, N. V., Prljić, J., Veljković, V., Mantlo, E., Bukreyeva, N., Paessler, S.,& Glišić, S. (2019). Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.
Frontiers in Cellular and Infection Microbiology, 9(MAR).
https://doi.org/10.3389/fcimb.2019.00067
Radošević D, Senćanski MV, Perović VR, Veljković NV, Prljić J, Veljković V, Mantlo E, Bukreyeva N, Paessler S, Glišić S. Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. Frontiers in Cellular and Infection Microbiology. 2019;9(MAR)
Radošević Draginja, Senćanski Milan V., Perović Vladimir R., Veljković Nevena V., Prljić Jelena, Veljković Veljko, Mantlo Emily, Bukreyeva Natalya, Paessler Slobodan, Glišić Sanja, "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors" Frontiers in Cellular and Infection Microbiology, 9, no. MAR (2019),
https://doi.org/10.3389/fcimb.2019.00067 .
1
5
4
4

Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets

Stevanović, Strahinja; Senćanski, Milan V.; Danel, Mathieu; Menendez, Christophe; Belguedj, Roumaissa; Bouraiou, Abdelmalek; Nikolić, Katarina M.; Cojean, Sandrine; Loiseau, Philippe Marie; Glišić, Sanja; Baltas, Michel; García-Sosa, Alfonso T.

(2019)

TY  - JOUR
AU  - Stevanović, Strahinja
AU  - Senćanski, Milan V.
AU  - Danel, Mathieu
AU  - Menendez, Christophe
AU  - Belguedj, Roumaissa
AU  - Bouraiou, Abdelmalek
AU  - Nikolić, Katarina M.
AU  - Cojean, Sandrine
AU  - Loiseau, Philippe Marie
AU  - Glišić, Sanja
AU  - Baltas, Michel
AU  - García-Sosa, Alfonso T.
PY  - 2019
UR  - https://www.mdpi.com/1420-3049/24/7/1282
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8137
AB  - Due to the lack of approved vaccines against human leishmaniasis and the limitations of the current chemotherapy inducing side effects and drug resistance, development of new, effective chemotherapeutic agents is essential. This study describes the synthesis of a series of novel oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite arginase. Top hits were further screened versus human arginase and finally against an anti-target battery to tag their possible interactions with proteins essential for the metabolism and clearance of many substances. Eight candidate compounds were selected for further experimental testing. The results show measurable in vitro anti-leishmanial activity for three compounds. One compound with an IC50 value of 2.18 µM on Leishmania donovani intramacrophage amastigotes is clearly better positioned than the others as an interesting molecular template for further development of new anti-leishmanial agents.
T2  - Molecules
T1  - Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets
VL  - 24
IS  - 7
SP  - 1282
DO  - 10.3390/molecules24071282
ER  - 
@article{
author = "Stevanović, Strahinja and Senćanski, Milan V. and Danel, Mathieu and Menendez, Christophe and Belguedj, Roumaissa and Bouraiou, Abdelmalek and Nikolić, Katarina M. and Cojean, Sandrine and Loiseau, Philippe Marie and Glišić, Sanja and Baltas, Michel and García-Sosa, Alfonso T.",
year = "2019",
url = "https://www.mdpi.com/1420-3049/24/7/1282, http://vinar.vin.bg.ac.rs/handle/123456789/8137",
abstract = "Due to the lack of approved vaccines against human leishmaniasis and the limitations of the current chemotherapy inducing side effects and drug resistance, development of new, effective chemotherapeutic agents is essential. This study describes the synthesis of a series of novel oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite arginase. Top hits were further screened versus human arginase and finally against an anti-target battery to tag their possible interactions with proteins essential for the metabolism and clearance of many substances. Eight candidate compounds were selected for further experimental testing. The results show measurable in vitro anti-leishmanial activity for three compounds. One compound with an IC50 value of 2.18 µM on Leishmania donovani intramacrophage amastigotes is clearly better positioned than the others as an interesting molecular template for further development of new anti-leishmanial agents.",
journal = "Molecules",
title = "Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets",
volume = "24",
number = "7",
pages = "1282",
doi = "10.3390/molecules24071282"
}
Stevanović, S., Senćanski, M. V., Danel, M., Menendez, C., Belguedj, R., Bouraiou, A., Nikolić, K. M., Cojean, S., Loiseau, P. M., Glišić, S., Baltas, M.,& García-Sosa, A. T. (2019). Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets.
Molecules, 24(7), 1282.
https://doi.org/10.3390/molecules24071282
Stevanović S, Senćanski MV, Danel M, Menendez C, Belguedj R, Bouraiou A, Nikolić KM, Cojean S, Loiseau PM, Glišić S, Baltas M, García-Sosa AT. Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets. Molecules. 2019;24(7):1282
Stevanović Strahinja, Senćanski Milan V., Danel Mathieu, Menendez Christophe, Belguedj Roumaissa, Bouraiou Abdelmalek, Nikolić Katarina M., Cojean Sandrine, Loiseau Philippe Marie, Glišić Sanja, Baltas Michel, García-Sosa Alfonso T., "Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets" Molecules, 24, no. 7 (2019):1282,
https://doi.org/10.3390/molecules24071282 .
4
5
4
5

Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy

Jovanović, Mirna; Zhukovsky, Daniil; Podolski-Renić, Ana; Domračeva, Ilona; Žalubovskis, Raivis; Senćanski, Milan V.; Glišić, Sanja; Sharoyko, Vladimir; Tennikova, Tatiana; Dar'in, Dmitry; Pešić, Milica; Krasavin, Mikhail

(2019)

TY  - JOUR
AU  - Jovanović, Mirna
AU  - Zhukovsky, Daniil
AU  - Podolski-Renić, Ana
AU  - Domračeva, Ilona
AU  - Žalubovskis, Raivis
AU  - Senćanski, Milan V.
AU  - Glišić, Sanja
AU  - Sharoyko, Vladimir
AU  - Tennikova, Tatiana
AU  - Dar'in, Dmitry
AU  - Pešić, Milica
AU  - Krasavin, Mikhail
PY  - 2019
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8532
AB  - A series of peptidomimetic compounds incorporating an electrophilic moiety was synthesized using the Ugi reaction. These compounds (termed the Ugi Michael acceptors or UMAs) were designed to target the selenocysteine catalytic residue of thioredoxin reductase 1 (TrxR1), a promising cancer target. The compounds were assessed for their potential to inhibit TrxR1 using human neuroblastoma (SH-SY5Y) cell lysate. Based on this initial screening, six compounds were selected for testing against recombinant rat TrxR1 and in the insulin assay to reveal low-micromolar to submicromolar potency of these inhibitors. The same frontrunner compounds were evaluated for their ability to exert antiproliferative activity and induce cell death and this activity was compared to the UMA effects on the levels of reactive oxygen and nitrogen species (RONS). Collectively, the UMA compounds class presented itself as a rich source of leads for TrxR1 inhibitor discovery for anticancer application. Compound 7 (DVD-445) was nominated a lead for further optimization. © 2019 Elsevier Masson SAS
T2  - European Journal of Medicinal Chemistry
T1  - Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy
VL  - 181
SP  - 111580
DO  - 10.1016/j.ejmech.2019.111580
ER  - 
@article{
author = "Jovanović, Mirna and Zhukovsky, Daniil and Podolski-Renić, Ana and Domračeva, Ilona and Žalubovskis, Raivis and Senćanski, Milan V. and Glišić, Sanja and Sharoyko, Vladimir and Tennikova, Tatiana and Dar'in, Dmitry and Pešić, Milica and Krasavin, Mikhail",
year = "2019",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/8532",
abstract = "A series of peptidomimetic compounds incorporating an electrophilic moiety was synthesized using the Ugi reaction. These compounds (termed the Ugi Michael acceptors or UMAs) were designed to target the selenocysteine catalytic residue of thioredoxin reductase 1 (TrxR1), a promising cancer target. The compounds were assessed for their potential to inhibit TrxR1 using human neuroblastoma (SH-SY5Y) cell lysate. Based on this initial screening, six compounds were selected for testing against recombinant rat TrxR1 and in the insulin assay to reveal low-micromolar to submicromolar potency of these inhibitors. The same frontrunner compounds were evaluated for their ability to exert antiproliferative activity and induce cell death and this activity was compared to the UMA effects on the levels of reactive oxygen and nitrogen species (RONS). Collectively, the UMA compounds class presented itself as a rich source of leads for TrxR1 inhibitor discovery for anticancer application. Compound 7 (DVD-445) was nominated a lead for further optimization. © 2019 Elsevier Masson SAS",
journal = "European Journal of Medicinal Chemistry",
title = "Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy",
volume = "181",
pages = "111580",
doi = "10.1016/j.ejmech.2019.111580"
}
Jovanović, M., Zhukovsky, D., Podolski-Renić, A., Domračeva, I., Žalubovskis, R., Senćanski, M. V., Glišić, S., Sharoyko, V., Tennikova, T., Dar'in, D., Pešić, M.,& Krasavin, M. (2019). Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.
European Journal of Medicinal Chemistry, 181, 111580.
https://doi.org/10.1016/j.ejmech.2019.111580
Jovanović M, Zhukovsky D, Podolski-Renić A, Domračeva I, Žalubovskis R, Senćanski MV, Glišić S, Sharoyko V, Tennikova T, Dar'in D, Pešić M, Krasavin M. Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy. European Journal of Medicinal Chemistry. 2019;181:111580
Jovanović Mirna, Zhukovsky Daniil, Podolski-Renić Ana, Domračeva Ilona, Žalubovskis Raivis, Senćanski Milan V., Glišić Sanja, Sharoyko Vladimir, Tennikova Tatiana, Dar'in Dmitry, Pešić Milica, Krasavin Mikhail, "Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy" European Journal of Medicinal Chemistry, 181 (2019):111580,
https://doi.org/10.1016/j.ejmech.2019.111580 .
1
11
10
10

Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR)

Senćanski, Milan V.; Glišić, Sanja; Šnajder, Marko; Veljković, Nevena V.; Poklar Ulrih, Nataša; Mavri, Janez; Vrecl, Milka

(2019)

TY  - JOUR
AU  - Senćanski, Milan V.
AU  - Glišić, Sanja
AU  - Šnajder, Marko
AU  - Veljković, Nevena V.
AU  - Poklar Ulrih, Nataša
AU  - Mavri, Janez
AU  - Vrecl, Milka
PY  - 2019
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8648
AB  - This study aimed to design and functionally characterize peptide mimetics of the nanobody (Nb) related to the β2-adrenergic receptor (β2-AR) (nanobody-derived peptide, NDP). We postulated that the computationally derived and optimized complementarity-determining region 3 (CDR3) of Nb is sufficient for its interaction with receptor. Sequence-related Nb-families preferring the agonist-bound active conformation of β2-AR were analysed using the informational spectrum method (ISM) and β2-AR:NDP complexes studied using protein-peptide docking and molecular dynamics (MD) simulations in conjunction with metadynamics calculations of free energy binding. The selected NDP of Nb71, designated P3, was 17 amino acids long and included CDR3. Metadynamics calculations yielded a binding free energy for the β2-AR:P3 complex of ΔG = (−7.23 ± 0.04) kcal/mol, or a Kd of (7.9 ± 0.5) μM, for T = 310 K. In vitro circular dichroism (CD) spectropolarimetry and microscale thermophoresis (MST) data provided additional evidence for P3 interaction with agonist-activated β2-AR, which displayed ~10-fold higher affinity for P3 than the unstimulated receptor (MST-derived EC50 of 3.57 µM vs. 58.22 µM), while its ability to inhibit the agonist-induced interaction of β2-AR with β-arrestin 2 was less evident. In summary, theoretical and experimental evidence indicated that P3 preferentially binds agonist-activated β2-AR. © 2019, The Author(s).
T2  - Scientific Reports
T1  - Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR)
VL  - 9
IS  - 1
SP  - 16555
DO  - 10.1038/s41598-019-52934-8
ER  - 
@article{
author = "Senćanski, Milan V. and Glišić, Sanja and Šnajder, Marko and Veljković, Nevena V. and Poklar Ulrih, Nataša and Mavri, Janez and Vrecl, Milka",
year = "2019",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/8648",
abstract = "This study aimed to design and functionally characterize peptide mimetics of the nanobody (Nb) related to the β2-adrenergic receptor (β2-AR) (nanobody-derived peptide, NDP). We postulated that the computationally derived and optimized complementarity-determining region 3 (CDR3) of Nb is sufficient for its interaction with receptor. Sequence-related Nb-families preferring the agonist-bound active conformation of β2-AR were analysed using the informational spectrum method (ISM) and β2-AR:NDP complexes studied using protein-peptide docking and molecular dynamics (MD) simulations in conjunction with metadynamics calculations of free energy binding. The selected NDP of Nb71, designated P3, was 17 amino acids long and included CDR3. Metadynamics calculations yielded a binding free energy for the β2-AR:P3 complex of ΔG = (−7.23 ± 0.04) kcal/mol, or a Kd of (7.9 ± 0.5) μM, for T = 310 K. In vitro circular dichroism (CD) spectropolarimetry and microscale thermophoresis (MST) data provided additional evidence for P3 interaction with agonist-activated β2-AR, which displayed ~10-fold higher affinity for P3 than the unstimulated receptor (MST-derived EC50 of 3.57 µM vs. 58.22 µM), while its ability to inhibit the agonist-induced interaction of β2-AR with β-arrestin 2 was less evident. In summary, theoretical and experimental evidence indicated that P3 preferentially binds agonist-activated β2-AR. © 2019, The Author(s).",
journal = "Scientific Reports",
title = "Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR)",
volume = "9",
number = "1",
pages = "16555",
doi = "10.1038/s41598-019-52934-8"
}
Senćanski, M. V., Glišić, S., Šnajder, M., Veljković, N. V., Poklar Ulrih, N., Mavri, J.,& Vrecl, M. (2019). Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR).
Scientific Reports, 9(1), 16555.
https://doi.org/10.1038/s41598-019-52934-8
Senćanski MV, Glišić S, Šnajder M, Veljković NV, Poklar Ulrih N, Mavri J, Vrecl M. Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR). Scientific Reports. 2019;9(1):16555
Senćanski Milan V., Glišić Sanja, Šnajder Marko, Veljković Nevena V., Poklar Ulrih Nataša, Mavri Janez, Vrecl Milka, "Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR)" Scientific Reports, 9, no. 1 (2019):16555,
https://doi.org/10.1038/s41598-019-52934-8 .
4
7
1
3

Functional characterization of β2-adrenergic and insulin receptor heteromers

Susec, Maja; Senćanski, Milan V.; Glišić, Sanja; Veljković, Nevena V.; Pedersen, Christina; Drinovec, Luka; Stojan, Jurij; Nøhr, Jane; Vrecl, Milka

(2019)

TY  - JOUR
AU  - Susec, Maja
AU  - Senćanski, Milan V.
AU  - Glišić, Sanja
AU  - Veljković, Nevena V.
AU  - Pedersen, Christina
AU  - Drinovec, Luka
AU  - Stojan, Jurij
AU  - Nøhr, Jane
AU  - Vrecl, Milka
PY  - 2019
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8490
AB  - This study aimed to functionally characterize β2-adrenergic (β2AR) and insulin receptor (IR) heteromers in regard to β-arrestin 2 (βarr2) recruitment and cAMP signaling and to examine the involvement of the cytoplasmic portion of the IR β chain in heteromerization with β2AR. Evidence for β2AR:IR:βarr2 complex formation and the specificity of the IR:βarr2 interaction was first provided by bioinfomatics analysis. Receptor-heteromer investigation technology (HIT) then provided functional evidence of β2AR:IR heterodimerization by showing isoproterenol-induced but not insulin-induced GFP2-βarr2 recruitment to the β2AR:IR complex; the IR:βarr2 interaction was found to only be constitutive. The constitutive IR:βarr2 BRET signal (BRETconst) was significantly smaller in cells coexpressing IR-RLuc8 and a GFP2-βarr2 1–185 mutant lacking the proposed IR binding domain. β2AR:IR heteromerization also influenced the pharmacological phenotype of β2AR, i.e., its efficacy in recruiting βarr2 and activating cAMP signaling. Evidence suggesting involvement of the cytoplasmic portion of the IR β chain in the interaction with β2AR was provided by BRET2 saturation and HIT assays using an IR 1–1271 stop mutant lacking the IR C-terminal tail region. For the complex consisting of IR 1–1271–RLuc8:β2AR-GFP2, saturation was not reached, most likely reflecting random collisions between IR 1–1271 and β2AR. Furthermore, in the HIT assay, no substantial agonist-induced increase in the BRET2 signal was detected that would be indicative of βarr2 recruitment to the IR 1–1271:β2AR heteromer. Complementary 3D visualization of β2AR:IR provided supporting evidence for stability of the heterotetramer complex and identified amino acid residues involved in β2AR:IR heteromerization. © 2019
T2  - Neuropharmacology
T1  - Functional characterization of β2-adrenergic and insulin receptor heteromers
VL  - 152
SP  - 78
EP  - 89
DO  - 10.1016/j.neuropharm.2019.01.025
ER  - 
@article{
author = "Susec, Maja and Senćanski, Milan V. and Glišić, Sanja and Veljković, Nevena V. and Pedersen, Christina and Drinovec, Luka and Stojan, Jurij and Nøhr, Jane and Vrecl, Milka",
year = "2019",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/8490",
abstract = "This study aimed to functionally characterize β2-adrenergic (β2AR) and insulin receptor (IR) heteromers in regard to β-arrestin 2 (βarr2) recruitment and cAMP signaling and to examine the involvement of the cytoplasmic portion of the IR β chain in heteromerization with β2AR. Evidence for β2AR:IR:βarr2 complex formation and the specificity of the IR:βarr2 interaction was first provided by bioinfomatics analysis. Receptor-heteromer investigation technology (HIT) then provided functional evidence of β2AR:IR heterodimerization by showing isoproterenol-induced but not insulin-induced GFP2-βarr2 recruitment to the β2AR:IR complex; the IR:βarr2 interaction was found to only be constitutive. The constitutive IR:βarr2 BRET signal (BRETconst) was significantly smaller in cells coexpressing IR-RLuc8 and a GFP2-βarr2 1–185 mutant lacking the proposed IR binding domain. β2AR:IR heteromerization also influenced the pharmacological phenotype of β2AR, i.e., its efficacy in recruiting βarr2 and activating cAMP signaling. Evidence suggesting involvement of the cytoplasmic portion of the IR β chain in the interaction with β2AR was provided by BRET2 saturation and HIT assays using an IR 1–1271 stop mutant lacking the IR C-terminal tail region. For the complex consisting of IR 1–1271–RLuc8:β2AR-GFP2, saturation was not reached, most likely reflecting random collisions between IR 1–1271 and β2AR. Furthermore, in the HIT assay, no substantial agonist-induced increase in the BRET2 signal was detected that would be indicative of βarr2 recruitment to the IR 1–1271:β2AR heteromer. Complementary 3D visualization of β2AR:IR provided supporting evidence for stability of the heterotetramer complex and identified amino acid residues involved in β2AR:IR heteromerization. © 2019",
journal = "Neuropharmacology",
title = "Functional characterization of β2-adrenergic and insulin receptor heteromers",
volume = "152",
pages = "78-89",
doi = "10.1016/j.neuropharm.2019.01.025"
}
Susec, M., Senćanski, M. V., Glišić, S., Veljković, N. V., Pedersen, C., Drinovec, L., Stojan, J., Nøhr, J.,& Vrecl, M. (2019). Functional characterization of β2-adrenergic and insulin receptor heteromers.
Neuropharmacology, 152, 78-89.
https://doi.org/10.1016/j.neuropharm.2019.01.025
Susec M, Senćanski MV, Glišić S, Veljković NV, Pedersen C, Drinovec L, Stojan J, Nøhr J, Vrecl M. Functional characterization of β2-adrenergic and insulin receptor heteromers. Neuropharmacology. 2019;152:78-89
Susec Maja, Senćanski Milan V., Glišić Sanja, Veljković Nevena V., Pedersen Christina, Drinovec Luka, Stojan Jurij, Nøhr Jane, Vrecl Milka, "Functional characterization of β2-adrenergic and insulin receptor heteromers" Neuropharmacology, 152 (2019):78-89,
https://doi.org/10.1016/j.neuropharm.2019.01.025 .
3
2
3

In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum

Stevanović, Strahinja; Perdih, Andrej; Senćanski, Milan V.; Glišić, Sanja; Duarte, Margarida; Tomas, Ana; Sena, Filipa; Sousa, Filipe; Pereira, Manuela M.; Šolmajer, Tom

(2018)

TY  - JOUR
AU  - Stevanović, Strahinja
AU  - Perdih, Andrej
AU  - Senćanski, Milan V.
AU  - Glišić, Sanja
AU  - Duarte, Margarida
AU  - Tomas, Ana
AU  - Sena, Filipa
AU  - Sousa, Filipe
AU  - Pereira, Manuela M.
AU  - Šolmajer, Tom
PY  - 2018
UR  - http://www.mdpi.com/1420-3049/23/4/772
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/7774
AB  - There is an urgent need for the discovery of new antileishmanial drugs with a new mechanism of action. Type 2 NADH dehydrogenase from Leishmania infantum (LiNDH2) is an enzyme of the parasite's respiratory system, which catalyzes the electron transfer from NADH to ubiquinone without coupled proton pumping. In previous studies of the related NADH: ubiquinone oxidoreductase crystal structure from Saccharomyces cerevisiae, two ubiquinone-binding sites (UQI and UQII) were identified and shown to play an important role in the NDH-2-catalyzed oxidoreduction reaction. Based on the available structural data, we developed a three-dimensional structural model of LiNDH2 using homology detection methods and performed an in silico virtual screening campaign to search for potential inhibitors targeting the LiNDH2 ubiquinone-binding site 1-UQI. Selected compounds displaying favorable properties in the computational screening experiments were assayed for inhibitory activity in the structurally similar recombinant NDH-2 from S. aureus and leishmanicidal activity was determined in the wild-type axenic amastigotes and promastigotes of L. infantum. The identified compound, a substituted 6-methoxy-quinalidine, showed promising nanomolar leishmanicidal activity on wild-type axenic promastigotes and amastigotes of L. infantum and the potential for further development.
T2  - Molecules
T1  - In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum
VL  - 23
IS  - 4
SP  - 772
DO  - 10.3390/molecules23040772
ER  - 
@article{
author = "Stevanović, Strahinja and Perdih, Andrej and Senćanski, Milan V. and Glišić, Sanja and Duarte, Margarida and Tomas, Ana and Sena, Filipa and Sousa, Filipe and Pereira, Manuela M. and Šolmajer, Tom",
year = "2018",
url = "http://www.mdpi.com/1420-3049/23/4/772, http://vinar.vin.bg.ac.rs/handle/123456789/7774",
abstract = "There is an urgent need for the discovery of new antileishmanial drugs with a new mechanism of action. Type 2 NADH dehydrogenase from Leishmania infantum (LiNDH2) is an enzyme of the parasite's respiratory system, which catalyzes the electron transfer from NADH to ubiquinone without coupled proton pumping. In previous studies of the related NADH: ubiquinone oxidoreductase crystal structure from Saccharomyces cerevisiae, two ubiquinone-binding sites (UQI and UQII) were identified and shown to play an important role in the NDH-2-catalyzed oxidoreduction reaction. Based on the available structural data, we developed a three-dimensional structural model of LiNDH2 using homology detection methods and performed an in silico virtual screening campaign to search for potential inhibitors targeting the LiNDH2 ubiquinone-binding site 1-UQI. Selected compounds displaying favorable properties in the computational screening experiments were assayed for inhibitory activity in the structurally similar recombinant NDH-2 from S. aureus and leishmanicidal activity was determined in the wild-type axenic amastigotes and promastigotes of L. infantum. The identified compound, a substituted 6-methoxy-quinalidine, showed promising nanomolar leishmanicidal activity on wild-type axenic promastigotes and amastigotes of L. infantum and the potential for further development.",
journal = "Molecules",
title = "In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum",
volume = "23",
number = "4",
pages = "772",
doi = "10.3390/molecules23040772"
}
Stevanović, S., Perdih, A., Senćanski, M. V., Glišić, S., Duarte, M., Tomas, A., Sena, F., Sousa, F., Pereira, M. M.,& Šolmajer, T. (2018). In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum.
Molecules, 23(4), 772.
https://doi.org/10.3390/molecules23040772
Stevanović S, Perdih A, Senćanski MV, Glišić S, Duarte M, Tomas A, Sena F, Sousa F, Pereira MM, Šolmajer T. In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum. Molecules. 2018;23(4):772
Stevanović Strahinja, Perdih Andrej, Senćanski Milan V., Glišić Sanja, Duarte Margarida, Tomas Ana, Sena Filipa, Sousa Filipe, Pereira Manuela M., Šolmajer Tom, "In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum" Molecules, 23, no. 4 (2018):772,
https://doi.org/10.3390/molecules23040772 .
1
14
12
13

Ibuprofen as a template molecule for drug design against Ebola virus

Paessler, Slobodan; Huang, Cheng; Senćanski, Milan V.; Veljković, Nevena V.; Perović, Vladimir R.; Glišić, Sanja; Veljković, Veljko

(2018)

TY  - JOUR
AU  - Paessler, Slobodan
AU  - Huang, Cheng
AU  - Senćanski, Milan V.
AU  - Veljković, Nevena V.
AU  - Perović, Vladimir R.
AU  - Glišić, Sanja
AU  - Veljković, Veljko
PY  - 2018
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/7695
AB  - The Ebola virus outbreak in West Africa 2015 and Congo 2017, point out an urgent need for development of drugs against this important pathogen. Previously, by repurposing virtual screening of 6438 drugs from DrugBank, ibuprofen was selected as a possible inhibitor of the Ebola virus infection. The results of an additional docking analysis as well as experimental results showing measurable anti-Ebola effect of ibuprofen in cell culture suggest ibuprofen as a promising molecular template for the development of drugs for treatment of the infection by Ebola virus.
T2  - Frontiers in Bioscience - Landmark
T1  - Ibuprofen as a template molecule for drug design against Ebola virus
VL  - 23
IS  - 5
SP  - 947
EP  - 953
ER  - 
@article{
author = "Paessler, Slobodan and Huang, Cheng and Senćanski, Milan V. and Veljković, Nevena V. and Perović, Vladimir R. and Glišić, Sanja and Veljković, Veljko",
year = "2018",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/7695",
abstract = "The Ebola virus outbreak in West Africa 2015 and Congo 2017, point out an urgent need for development of drugs against this important pathogen. Previously, by repurposing virtual screening of 6438 drugs from DrugBank, ibuprofen was selected as a possible inhibitor of the Ebola virus infection. The results of an additional docking analysis as well as experimental results showing measurable anti-Ebola effect of ibuprofen in cell culture suggest ibuprofen as a promising molecular template for the development of drugs for treatment of the infection by Ebola virus.",
journal = "Frontiers in Bioscience - Landmark",
title = "Ibuprofen as a template molecule for drug design against Ebola virus",
volume = "23",
number = "5",
pages = "947-953"
}
Paessler, S., Huang, C., Senćanski, M. V., Veljković, N. V., Perović, V. R., Glišić, S.,& Veljković, V. (2018). Ibuprofen as a template molecule for drug design against Ebola virus.
Frontiers in Bioscience - Landmark, 23(5), 947-953.
Paessler S, Huang C, Senćanski MV, Veljković NV, Perović VR, Glišić S, Veljković V. Ibuprofen as a template molecule for drug design against Ebola virus. Frontiers in Bioscience - Landmark. 2018;23(5):947-953
Paessler Slobodan, Huang Cheng, Senćanski Milan V., Veljković Nevena V., Perović Vladimir R., Glišić Sanja, Veljković Veljko, "Ibuprofen as a template molecule for drug design against Ebola virus" Frontiers in Bioscience - Landmark, 23, no. 5 (2018):947-953
13

Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in ChronicTinnitus

Bojić, Tijana; Perović, Vladimir R.; Senćanski, Milan V.; Glišić, Sanja

(2017)

TY  - JOUR
AU  - Bojić, Tijana
AU  - Perović, Vladimir R.
AU  - Senćanski, Milan V.
AU  - Glišić, Sanja
PY  - 2017
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1823
AB  - Chronic tinnitus is characterized by neuroplastic changes of the auditory cortex. A promising method for therapy of chronic tinnitus is vagus nerve stimulation (VNS) combined with auditory stimulation. The principle of VNS is reversal of pathological neuroplastic changes of the auditory cortex toward physiological neural activity and synchronicity. The VNS mechanism of action in chronic tinnitus patients is prevailingly through the muscarinic neuromodulation of the auditory cortex by the activation of nc. basalis Meynerti. The aim of this study is to propose potential pharmaceutics which may improve the neuromodulatory effects of VNS. The working hypothesis is that M1 receptors have a dominant role in the neural plasticity of the auditory cortex. We propose that allosteric agonists of the muscarinic receptor type 1 (M1) receptor could improve specificity and selectivity of the neuromodulatory effect of VNS on the auditory cortex of chronic tinnitus patients even in the circumstances of lower acetylcholine brain concentration. This intervention would also reinforce the re-learning process of tinnitus (sub) networks by acting on cholinergic memory and learning mechanisms. We performed in silico screening of drug space using the EIIP/AQVN filter and selected 50 drugs as candidates for allosteric modulators of muscarinic receptors. Further filtering of these compounds by means of 3D QSAR and docking revealed 3 approved drugs-bromazepam, estazolam and flumazenil as the most promising candidates for combined chronic tinnitus therapy. These drugs should be further evaluated by biological tests and clinical trials.
T2  - Frontiers in Neuroscience
T1  - Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in ChronicTinnitus
VL  - 11
SP  - 636
DO  - 10.3389/fnins.2017.00636
ER  - 
@article{
author = "Bojić, Tijana and Perović, Vladimir R. and Senćanski, Milan V. and Glišić, Sanja",
year = "2017",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1823",
abstract = "Chronic tinnitus is characterized by neuroplastic changes of the auditory cortex. A promising method for therapy of chronic tinnitus is vagus nerve stimulation (VNS) combined with auditory stimulation. The principle of VNS is reversal of pathological neuroplastic changes of the auditory cortex toward physiological neural activity and synchronicity. The VNS mechanism of action in chronic tinnitus patients is prevailingly through the muscarinic neuromodulation of the auditory cortex by the activation of nc. basalis Meynerti. The aim of this study is to propose potential pharmaceutics which may improve the neuromodulatory effects of VNS. The working hypothesis is that M1 receptors have a dominant role in the neural plasticity of the auditory cortex. We propose that allosteric agonists of the muscarinic receptor type 1 (M1) receptor could improve specificity and selectivity of the neuromodulatory effect of VNS on the auditory cortex of chronic tinnitus patients even in the circumstances of lower acetylcholine brain concentration. This intervention would also reinforce the re-learning process of tinnitus (sub) networks by acting on cholinergic memory and learning mechanisms. We performed in silico screening of drug space using the EIIP/AQVN filter and selected 50 drugs as candidates for allosteric modulators of muscarinic receptors. Further filtering of these compounds by means of 3D QSAR and docking revealed 3 approved drugs-bromazepam, estazolam and flumazenil as the most promising candidates for combined chronic tinnitus therapy. These drugs should be further evaluated by biological tests and clinical trials.",
journal = "Frontiers in Neuroscience",
title = "Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in ChronicTinnitus",
volume = "11",
pages = "636",
doi = "10.3389/fnins.2017.00636"
}
Bojić, T., Perović, V. R., Senćanski, M. V.,& Glišić, S. (2017). Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in ChronicTinnitus.
Frontiers in Neuroscience, 11, 636.
https://doi.org/10.3389/fnins.2017.00636
Bojić T, Perović VR, Senćanski MV, Glišić S. Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in ChronicTinnitus. Frontiers in Neuroscience. 2017;11:636
Bojić Tijana, Perović Vladimir R., Senćanski Milan V., Glišić Sanja, "Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in ChronicTinnitus" Frontiers in Neuroscience, 11 (2017):636,
https://doi.org/10.3389/fnins.2017.00636 .
2
3
3
3

Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China

Veljković, Veljko; Veljković, Nevena V.; Paessler, Slobodan; Goeijenbier, Marco; Perović, Vladimir R.; Glišić, Sanja; Muller, Claude P.

(2016)

TY  - JOUR
AU  - Veljković, Veljko
AU  - Veljković, Nevena V.
AU  - Paessler, Slobodan
AU  - Goeijenbier, Marco
AU  - Perović, Vladimir R.
AU  - Glišić, Sanja
AU  - Muller, Claude P.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1300
AB  - Influenza A virus (IAV) subtypes against which little or no pre-existing immunity exists in humans represent a serious threat to global public health. Monitoring of IAV in animal hosts is essential for early and rapid detection of potential pandemic IAV strains to prevent their spread. Recently, the increased pandemic potential of the avian-like swine H1N1 IAV A/swine/Guangdong/104/2013 has been suggested. The virus is infectious in humans and the general population seems to lack neutralizing antibodies against this virus. Here we present an in silico analysis that shows a strong human propensity of this swine virus further confirming its pandemic potential. We suggest mutations which would further enhance its human propensity. We also propose conserved antigenic determinants which could serve as a component of a prepandemic vaccine. The bioinformatics tool, which can be used to further monitor the evolution of swine influenza viruses towards a pandemic virus, are described here and are made publically available (http://www.vin.bg.ac.rs/180/tools/iav_ mon.php;http://www.biomedprotection.com/iav_mon.php).
T2  - PLOS One
T1  - Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China
VL  - 11
IS  - 11
DO  - 10.1371/journal.pone.0165451
ER  - 
@article{
author = "Veljković, Veljko and Veljković, Nevena V. and Paessler, Slobodan and Goeijenbier, Marco and Perović, Vladimir R. and Glišić, Sanja and Muller, Claude P.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1300",
abstract = "Influenza A virus (IAV) subtypes against which little or no pre-existing immunity exists in humans represent a serious threat to global public health. Monitoring of IAV in animal hosts is essential for early and rapid detection of potential pandemic IAV strains to prevent their spread. Recently, the increased pandemic potential of the avian-like swine H1N1 IAV A/swine/Guangdong/104/2013 has been suggested. The virus is infectious in humans and the general population seems to lack neutralizing antibodies against this virus. Here we present an in silico analysis that shows a strong human propensity of this swine virus further confirming its pandemic potential. We suggest mutations which would further enhance its human propensity. We also propose conserved antigenic determinants which could serve as a component of a prepandemic vaccine. The bioinformatics tool, which can be used to further monitor the evolution of swine influenza viruses towards a pandemic virus, are described here and are made publically available (http://www.vin.bg.ac.rs/180/tools/iav_ mon.php;http://www.biomedprotection.com/iav_mon.php).",
journal = "PLOS One",
title = "Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China",
volume = "11",
number = "11",
doi = "10.1371/journal.pone.0165451"
}
Veljković, V., Veljković, N. V., Paessler, S., Goeijenbier, M., Perović, V. R., Glišić, S.,& Muller, C. P. (2016). Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China.
PLOS One, 11(11).
https://doi.org/10.1371/journal.pone.0165451
Veljković V, Veljković NV, Paessler S, Goeijenbier M, Perović VR, Glišić S, Muller CP. Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. PLOS One. 2016;11(11)
Veljković Veljko, Veljković Nevena V., Paessler Slobodan, Goeijenbier Marco, Perović Vladimir R., Glišić Sanja, Muller Claude P., "Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China" PLOS One, 11, no. 11 (2016),
https://doi.org/10.1371/journal.pone.0165451 .
2
2
1

An expanded evaluation of protein function prediction methods shows an improvement in accuracy

Jiang, Yuxiang; Gemović, Branislava S.; Glišić, Sanja; Perović, Vladimir R.; Veljković, Veljko; Veljković, Nevena V.

(2016)

TY  - JOUR
AU  - Jiang, Yuxiang
AU  - Gemović, Branislava S.
AU  - Glišić, Sanja
AU  - Perović, Vladimir R.
AU  - Veljković, Veljko
AU  - Veljković, Nevena V.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1244
AB  - Background: A major bottleneck in our understanding of the molecular underpinnings of life is the assignment of function to proteins. While molecular experiments provide the most reliable annotation of proteins, their relatively low throughput and restricted purview have led to an increasing role for computational function prediction. However, assessing methods for protein function prediction and tracking progress in the field remain challenging. Results: We conducted the second critical assessment of functional annotation (CAFA), a timed challenge to assess computational methods that automatically assign protein function. We evaluated 126 methods from 56 research groups for their ability to predict biological functions using Gene Ontology and gene-disease associations using Human Phenotype Ontology on a set of 3681 proteins from 18 species. CAFA2 featured expanded analysis compared with CAFA1, with regards to data set size, variety, and assessment metrics. To review progress in the field, the analysis compared the best methods from CAFA1 to those of CAFA2. Conclusions: The top-performing methods in CAFA2 outperformed those from CAFA1. This increased accuracy can be attributed to a combination of the growing number of experimental annotations and improved methods for function prediction. The assessment also revealed that the definition of top-performing algorithms is ontology specific, that different performance metrics can be used to probe the nature of accurate predictions, and the relative diversity of predictions in the biological process and human phenotype ontologies. While there was methodological improvement between CAFA1 and CAFA2, the interpretation of results and usefulness of individual methods remain context-dependent.
T2  - Genome Biology
T1  - An expanded evaluation of protein function prediction methods shows an improvement in accuracy
VL  - 17
DO  - 10.1186/s13059-016-1037-6
ER  - 
@article{
author = "Jiang, Yuxiang and Gemović, Branislava S. and Glišić, Sanja and Perović, Vladimir R. and Veljković, Veljko and Veljković, Nevena V.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1244",
abstract = "Background: A major bottleneck in our understanding of the molecular underpinnings of life is the assignment of function to proteins. While molecular experiments provide the most reliable annotation of proteins, their relatively low throughput and restricted purview have led to an increasing role for computational function prediction. However, assessing methods for protein function prediction and tracking progress in the field remain challenging. Results: We conducted the second critical assessment of functional annotation (CAFA), a timed challenge to assess computational methods that automatically assign protein function. We evaluated 126 methods from 56 research groups for their ability to predict biological functions using Gene Ontology and gene-disease associations using Human Phenotype Ontology on a set of 3681 proteins from 18 species. CAFA2 featured expanded analysis compared with CAFA1, with regards to data set size, variety, and assessment metrics. To review progress in the field, the analysis compared the best methods from CAFA1 to those of CAFA2. Conclusions: The top-performing methods in CAFA2 outperformed those from CAFA1. This increased accuracy can be attributed to a combination of the growing number of experimental annotations and improved methods for function prediction. The assessment also revealed that the definition of top-performing algorithms is ontology specific, that different performance metrics can be used to probe the nature of accurate predictions, and the relative diversity of predictions in the biological process and human phenotype ontologies. While there was methodological improvement between CAFA1 and CAFA2, the interpretation of results and usefulness of individual methods remain context-dependent.",
journal = "Genome Biology",
title = "An expanded evaluation of protein function prediction methods shows an improvement in accuracy",
volume = "17",
doi = "10.1186/s13059-016-1037-6"
}
Jiang, Y., Gemović, B. S., Glišić, S., Perović, V. R., Veljković, V.,& Veljković, N. V. (2016). An expanded evaluation of protein function prediction methods shows an improvement in accuracy.
Genome Biology, 17.
https://doi.org/10.1186/s13059-016-1037-6
Jiang Y, Gemović BS, Glišić S, Perović VR, Veljković V, Veljković NV. An expanded evaluation of protein function prediction methods shows an improvement in accuracy. Genome Biology. 2016;17
Jiang Yuxiang, Gemović Branislava S., Glišić Sanja, Perović Vladimir R., Veljković Veljko, Veljković Nevena V., "An expanded evaluation of protein function prediction methods shows an improvement in accuracy" Genome Biology, 17 (2016),
https://doi.org/10.1186/s13059-016-1037-6 .
32
238
143
160

Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3

Glišić, Sanja; Cavanaugh, David P.; Chittur, Krishnan K.; Senćanski, Milan V.; Perović, Vladimir R.; Bojić, Tijana

(2016)

TY  - JOUR
AU  - Glišić, Sanja
AU  - Cavanaugh, David P.
AU  - Chittur, Krishnan K.
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Bojić, Tijana
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/977
AB  - Background: The pathophysiological overlapping between Sjorgens Syndrome (SS) and HCV, presence of anti-muscarinic receptor type 3 (M3R) antibodies in SS, the role that M3R plays in the regulation of the heart rate, has led to the assumption that cardiovagal dysfunction in HCV patients is caused by anti-M3R antibodies elicited by HCV proteins or by their direct interaction with M3R. Results: To identify HCV protein which possibly is crossreactive with M3R or which binds to this receptor, we performed the Informational Spectrum Method (ISM) analysis of the HCV proteome. This analysis revealed that NS5A protein represents the most probable interactor of M3R or that this viral protein could elicit antibodies which modulate function of this receptor. Further detailed structure/function analysis of NS5A and M3R performed by the ISM method extended with other Digital Signal processing (DSP) approaches revealed domains of these proteins which participate in their crossreactivity or in their direct interaction, representing promising diagnostic and therapeutic targets. Conclusions: Application of the ISM with other compatible bioinformatics methods offers new perspectives for identifying diagnostic and therapeutic targets for complicated forms of HCV and other viral infections. We show how the electron-ion interaction potential (EIIP) amino-acid scale used in the ISM combined with a robust, high performance hydrophobicity scale can provide new insights for understanding protein structure/function and protein-protein interactions.
T2  - BMC Bioinformatics
T1  - Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3
VL  - 17
SP  - 139
DO  - 10.1186/s12859-016-0988-7
ER  - 
@article{
author = "Glišić, Sanja and Cavanaugh, David P. and Chittur, Krishnan K. and Senćanski, Milan V. and Perović, Vladimir R. and Bojić, Tijana",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/977",
abstract = "Background: The pathophysiological overlapping between Sjorgens Syndrome (SS) and HCV, presence of anti-muscarinic receptor type 3 (M3R) antibodies in SS, the role that M3R plays in the regulation of the heart rate, has led to the assumption that cardiovagal dysfunction in HCV patients is caused by anti-M3R antibodies elicited by HCV proteins or by their direct interaction with M3R. Results: To identify HCV protein which possibly is crossreactive with M3R or which binds to this receptor, we performed the Informational Spectrum Method (ISM) analysis of the HCV proteome. This analysis revealed that NS5A protein represents the most probable interactor of M3R or that this viral protein could elicit antibodies which modulate function of this receptor. Further detailed structure/function analysis of NS5A and M3R performed by the ISM method extended with other Digital Signal processing (DSP) approaches revealed domains of these proteins which participate in their crossreactivity or in their direct interaction, representing promising diagnostic and therapeutic targets. Conclusions: Application of the ISM with other compatible bioinformatics methods offers new perspectives for identifying diagnostic and therapeutic targets for complicated forms of HCV and other viral infections. We show how the electron-ion interaction potential (EIIP) amino-acid scale used in the ISM combined with a robust, high performance hydrophobicity scale can provide new insights for understanding protein structure/function and protein-protein interactions.",
journal = "BMC Bioinformatics",
title = "Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3",
volume = "17",
pages = "139",
doi = "10.1186/s12859-016-0988-7"
}
Glišić, S., Cavanaugh, D. P., Chittur, K. K., Senćanski, M. V., Perović, V. R.,& Bojić, T. (2016). Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3.
BMC Bioinformatics, 17, 139.
https://doi.org/10.1186/s12859-016-0988-7
Glišić S, Cavanaugh DP, Chittur KK, Senćanski MV, Perović VR, Bojić T. Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3. BMC Bioinformatics. 2016;17:139
Glišić Sanja, Cavanaugh David P., Chittur Krishnan K., Senćanski Milan V., Perović Vladimir R., Bojić Tijana, "Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3" BMC Bioinformatics, 17 (2016):139,
https://doi.org/10.1186/s12859-016-0988-7 .
4
4
5

In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope

Bojić, Tijana; Perović, Vladimir R.; Glišić, Sanja

(2016)

TY  - JOUR
AU  - Bojić, Tijana
AU  - Perović, Vladimir R.
AU  - Glišić, Sanja
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/900
AB  - Neurocardiovascular diseases (NCVD) are the leading cause of death in the developed world and will remain so till 2020. In these diseases the pathologically changed nervous control of cardiovascular system has the central role. The actual NCV syndromes are neurogenic hypertension, representing the sympathetically mediated disorder, and vasovagal syncope, which is the vagally mediated disorders. Vasovagal syncope, the disease far from its etiological treatment, could benefit from recruiting and application of antimuscarinic drugs used in other parasympathetic disorders. The informational spectrum method (ISM), a method widely applied for the characterization of protein-protein interactions in the field of immunology, endocrinology and anti HIV drug discovery, was applied for the first time in the analysis of neurogenic hypertension and vasovagal syncope therapeutic targets. In silico analysis revealed the potential involvement of apelin in neurogenic hypertension. Applying the EIIP/ISM bioinformatics concept in investigation of drugs for treatment of vasovagal syncope suggests that 78% of tested antimuscarinic drugs could have anti vasovagal syncope effect. The presented results confirm that ISM is a promissing method for investigation of molecular mechanisms underlying pathophysiological proceses of NCV syndromes and discovery of therapeutics targets for their treatment.
T2  - Frontiers in Neuroscience
T1  - In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope
VL  - 9
SP  - 520
DO  - 10.3389/fnins.2015.00520
ER  - 
@article{
author = "Bojić, Tijana and Perović, Vladimir R. and Glišić, Sanja",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/900",
abstract = "Neurocardiovascular diseases (NCVD) are the leading cause of death in the developed world and will remain so till 2020. In these diseases the pathologically changed nervous control of cardiovascular system has the central role. The actual NCV syndromes are neurogenic hypertension, representing the sympathetically mediated disorder, and vasovagal syncope, which is the vagally mediated disorders. Vasovagal syncope, the disease far from its etiological treatment, could benefit from recruiting and application of antimuscarinic drugs used in other parasympathetic disorders. The informational spectrum method (ISM), a method widely applied for the characterization of protein-protein interactions in the field of immunology, endocrinology and anti HIV drug discovery, was applied for the first time in the analysis of neurogenic hypertension and vasovagal syncope therapeutic targets. In silico analysis revealed the potential involvement of apelin in neurogenic hypertension. Applying the EIIP/ISM bioinformatics concept in investigation of drugs for treatment of vasovagal syncope suggests that 78% of tested antimuscarinic drugs could have anti vasovagal syncope effect. The presented results confirm that ISM is a promissing method for investigation of molecular mechanisms underlying pathophysiological proceses of NCV syndromes and discovery of therapeutics targets for their treatment.",
journal = "Frontiers in Neuroscience",
title = "In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope",
volume = "9",
pages = "520",
doi = "10.3389/fnins.2015.00520"
}
Bojić, T., Perović, V. R.,& Glišić, S. (2016). In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope.
Frontiers in Neuroscience, 9, 520.
https://doi.org/10.3389/fnins.2015.00520
Bojić T, Perović VR, Glišić S. In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope. Frontiers in Neuroscience. 2016;9:520
Bojić Tijana, Perović Vladimir R., Glišić Sanja, "In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope" Frontiers in Neuroscience, 9 (2016):520,
https://doi.org/10.3389/fnins.2015.00520 .
2
1
3
3

Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets

Glišić, Sanja; Senćanski, Milan V.; Perović, Vladimir R.; Stevanović, Strahinja; Garcia-Sosa, Alfonso T.

(2016)

TY  - JOUR
AU  - Glišić, Sanja
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Stevanović, Strahinja
AU  - Garcia-Sosa, Alfonso T.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1187
AB  - Arginase, a drug target for the treatment of leishmaniasis, is involved in the biosynthesis of polyamines. Flavonoids are interesting natural compounds found in many foods and some of them may inhibit this enzyme. The MetIDB database containing 5667 compounds was screened using an EIIP/AQVN filter and 3D QSAR to find the most promising candidate compounds. In addition, these top hits were screened in silico versus human arginase and an anti-target battery consisting of cytochromes P450 2a6, 2c9, 3a4, sulfotransferase, and the pregnane-X-receptor in order to flag their possible interactions with these proteins involved in the metabolism of substances. The resulting compounds may have promise to be further developed for the treatment of leishmaniasis.
T2  - Molecules
T1  - Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets
VL  - 21
IS  - 5
DO  - 10.3390/molecules21050589
ER  - 
@article{
author = "Glišić, Sanja and Senćanski, Milan V. and Perović, Vladimir R. and Stevanović, Strahinja and Garcia-Sosa, Alfonso T.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1187",
abstract = "Arginase, a drug target for the treatment of leishmaniasis, is involved in the biosynthesis of polyamines. Flavonoids are interesting natural compounds found in many foods and some of them may inhibit this enzyme. The MetIDB database containing 5667 compounds was screened using an EIIP/AQVN filter and 3D QSAR to find the most promising candidate compounds. In addition, these top hits were screened in silico versus human arginase and an anti-target battery consisting of cytochromes P450 2a6, 2c9, 3a4, sulfotransferase, and the pregnane-X-receptor in order to flag their possible interactions with these proteins involved in the metabolism of substances. The resulting compounds may have promise to be further developed for the treatment of leishmaniasis.",
journal = "Molecules",
title = "Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets",
volume = "21",
number = "5",
doi = "10.3390/molecules21050589"
}
Glišić, S., Senćanski, M. V., Perović, V. R., Stevanović, S.,& Garcia-Sosa, A. T. (2016). Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets.
Molecules, 21(5).
https://doi.org/10.3390/molecules21050589
Glišić S, Senćanski MV, Perović VR, Stevanović S, Garcia-Sosa AT. Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets. Molecules. 2016;21(5)
Glišić Sanja, Senćanski Milan V., Perović Vladimir R., Stevanović Strahinja, Garcia-Sosa Alfonso T., "Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets" Molecules, 21, no. 5 (2016),
https://doi.org/10.3390/molecules21050589 .
16
12
15

A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin

Vucicevic, Jelica; Srdić-Rajić, Tatjana; Pieroni, Marco; Laurila, Jonne M. M.; Perović, Vladimir R.; Tassini, Sabrina; Azzali, Elisa; Costantino, Gabriele; Glišić, Sanja; Agbaba, Danica; Scheinin, Mika; Nikolic, Katarina; Radi, Marco; Veljković, Nevena V.

(2016)

TY  - JOUR
AU  - Vucicevic, Jelica
AU  - Srdić-Rajić, Tatjana
AU  - Pieroni, Marco
AU  - Laurila, Jonne M. M.
AU  - Perović, Vladimir R.
AU  - Tassini, Sabrina
AU  - Azzali, Elisa
AU  - Costantino, Gabriele
AU  - Glišić, Sanja
AU  - Agbaba, Danica
AU  - Scheinin, Mika
AU  - Nikolic, Katarina
AU  - Radi, Marco
AU  - Veljković, Nevena V.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1110
AB  - The clonidine-like central antihypertensive agent rilmenidine, which has high affinity for I-1-type imidazoline receptors (I-1-IR) was recently found to have cytotoxic effects on cultured cancer cell lines. However, due to its pharmacological effects resulting also from alpha(2)-adrenoceptor activation, rilmenidine cannot be considered a suitable anticancer drug candidate. Here, we report the identification of novel rilmenidine- derived compounds with anticancer potential and devoid of alpha(2)-adrenoceptor effects by means of ligand-and structure-based drug design approaches. Starting from a large virtual library, eleven compounds were selected, synthesized and submitted to biological evaluation. The most active compound 5 exhibited a cytotoxic profile similar to that of rilmenidine, but without appreciable affinity to alpha(2)-adrenoceptors. In addition, compound 5 significantly enhanced the apoptotic response to doxorubicin, and may thus represent an important tool for the development of better adjuvant chemotherapeutic strategies for doxorubicin-insensitive cancers. (C) 2016 Elsevier Ltd. All rights reserved.
T2  - Bioorganic and Medicinal Chemistry
T1  - A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin
VL  - 24
IS  - 14
SP  - 3174
EP  - 3183
DO  - 10.1016/j.bmc.2016.05.043
ER  - 
@article{
author = "Vucicevic, Jelica and Srdić-Rajić, Tatjana and Pieroni, Marco and Laurila, Jonne M. M. and Perović, Vladimir R. and Tassini, Sabrina and Azzali, Elisa and Costantino, Gabriele and Glišić, Sanja and Agbaba, Danica and Scheinin, Mika and Nikolic, Katarina and Radi, Marco and Veljković, Nevena V.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1110",
abstract = "The clonidine-like central antihypertensive agent rilmenidine, which has high affinity for I-1-type imidazoline receptors (I-1-IR) was recently found to have cytotoxic effects on cultured cancer cell lines. However, due to its pharmacological effects resulting also from alpha(2)-adrenoceptor activation, rilmenidine cannot be considered a suitable anticancer drug candidate. Here, we report the identification of novel rilmenidine- derived compounds with anticancer potential and devoid of alpha(2)-adrenoceptor effects by means of ligand-and structure-based drug design approaches. Starting from a large virtual library, eleven compounds were selected, synthesized and submitted to biological evaluation. The most active compound 5 exhibited a cytotoxic profile similar to that of rilmenidine, but without appreciable affinity to alpha(2)-adrenoceptors. In addition, compound 5 significantly enhanced the apoptotic response to doxorubicin, and may thus represent an important tool for the development of better adjuvant chemotherapeutic strategies for doxorubicin-insensitive cancers. (C) 2016 Elsevier Ltd. All rights reserved.",
journal = "Bioorganic and Medicinal Chemistry",
title = "A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin",
volume = "24",
number = "14",
pages = "3174-3183",
doi = "10.1016/j.bmc.2016.05.043"
}
Vucicevic, J., Srdić-Rajić, T., Pieroni, M., Laurila, J. M. M., Perović, V. R., Tassini, S., Azzali, E., Costantino, G., Glišić, S., Agbaba, D., Scheinin, M., Nikolic, K., Radi, M.,& Veljković, N. V. (2016). A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.
Bioorganic and Medicinal Chemistry, 24(14), 3174-3183.
https://doi.org/10.1016/j.bmc.2016.05.043
Vucicevic J, Srdić-Rajić T, Pieroni M, Laurila JMM, Perović VR, Tassini S, Azzali E, Costantino G, Glišić S, Agbaba D, Scheinin M, Nikolic K, Radi M, Veljković NV. A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorganic and Medicinal Chemistry. 2016;24(14):3174-3183
Vucicevic Jelica, Srdić-Rajić Tatjana, Pieroni Marco, Laurila Jonne M. M., Perović Vladimir R., Tassini Sabrina, Azzali Elisa, Costantino Gabriele, Glišić Sanja, Agbaba Danica, Scheinin Mika, Nikolic Katarina, Radi Marco, Veljković Nevena V., "A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin" Bioorganic and Medicinal Chemistry, 24, no. 14 (2016):3174-3183,
https://doi.org/10.1016/j.bmc.2016.05.043 .
2
9
10
8

Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics

Veljković, Veljko; Glišić, Sanja; Perović, Vladimir R.; Veljković, Nevena V.; Nicolson, Garth L.

(2016)

TY  - JOUR
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Nicolson, Garth L.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1372
AB  - Background: Numerous in vitro and in vivo studies, in addition to clinical data, demonstrate that pomegranate juice can prevent or slow-down the progression of some types of cancers. Despite the well-documented effect of pomegranate ingredients on neoplastic changes, the molecular mechanism(s) underlying this phenomenon remains elusive. Methods: For the study of pomegranate ingredients the electron-ion interaction potential (EIIP) and the average quasi valence number (AQVN) were used. These molecular descriptors can be used to describe the long-range intermolecular interactions in biological systems and can identify substances with strong electron-acceptor properties. In this study, candidate human proteins interacting with pomegranate flavonoids have been analyzed by the informational spectrum method (ISM). This represents a virtual spectroscopy method for studying protein molecular interactions. Results: Our analysis indicates that the anti-cancer properties of pomegranate juice can be ascribed to the strong electron-acceptor properties of its chemical ingredients. This analysis also suggests that pomegranate flavonoids inhibit the NF-kappaB (NF-kappa B) pathway, which plays a critical role in the pathogenesis of cancer. Conclusion: The results offer a possible explanation for an important molecular mechanism underlying the anticancer activity of pomegranate ingredients, which could also serve as a basis for the development of new therapeutic compositions of food supplements with pomegranate-like anticancer properties.
T2  - Functional Foods in Health and Disease
T1  - Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics
VL  - 6
IS  - 12
SP  - 769
EP  - 787
ER  - 
@article{
author = "Veljković, Veljko and Glišić, Sanja and Perović, Vladimir R. and Veljković, Nevena V. and Nicolson, Garth L.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1372",
abstract = "Background: Numerous in vitro and in vivo studies, in addition to clinical data, demonstrate that pomegranate juice can prevent or slow-down the progression of some types of cancers. Despite the well-documented effect of pomegranate ingredients on neoplastic changes, the molecular mechanism(s) underlying this phenomenon remains elusive. Methods: For the study of pomegranate ingredients the electron-ion interaction potential (EIIP) and the average quasi valence number (AQVN) were used. These molecular descriptors can be used to describe the long-range intermolecular interactions in biological systems and can identify substances with strong electron-acceptor properties. In this study, candidate human proteins interacting with pomegranate flavonoids have been analyzed by the informational spectrum method (ISM). This represents a virtual spectroscopy method for studying protein molecular interactions. Results: Our analysis indicates that the anti-cancer properties of pomegranate juice can be ascribed to the strong electron-acceptor properties of its chemical ingredients. This analysis also suggests that pomegranate flavonoids inhibit the NF-kappaB (NF-kappa B) pathway, which plays a critical role in the pathogenesis of cancer. Conclusion: The results offer a possible explanation for an important molecular mechanism underlying the anticancer activity of pomegranate ingredients, which could also serve as a basis for the development of new therapeutic compositions of food supplements with pomegranate-like anticancer properties.",
journal = "Functional Foods in Health and Disease",
title = "Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics",
volume = "6",
number = "12",
pages = "769-787"
}
Veljković, V., Glišić, S., Perović, V. R., Veljković, N. V.,& Nicolson, G. L. (2016). Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics.
Functional Foods in Health and Disease, 6(12), 769-787.
Veljković V, Glišić S, Perović VR, Veljković NV, Nicolson GL. Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics. Functional Foods in Health and Disease. 2016;6(12):769-787
Veljković Veljko, Glišić Sanja, Perović Vladimir R., Veljković Nevena V., Nicolson Garth L., "Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics" Functional Foods in Health and Disease, 6, no. 12 (2016):769-787
1

The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia

Jovanović-Ćupić, Snežana P.; Glišić, Sanja; Stanojevic, Maja; Nozic, Darko; Petrović, Nina; Mandušić, Vesna; Krajnović, Milena M.

(2016)

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, Maja
AU  - Nozic, Darko
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1032
AB  - The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
T2  - Archives of Virology
T1  - The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
VL  - 161
IS  - 5
SP  - 1189
EP  - 1198
DO  - 10.1007/s00705-016-2777-z
ER  - 
@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, Maja and Nozic, Darko and Petrović, Nina and Mandušić, Vesna and Krajnović, Milena M.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1032",
abstract = "The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.",
journal = "Archives of Virology",
title = "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia",
volume = "161",
number = "5",
pages = "1189-1198",
doi = "10.1007/s00705-016-2777-z"
}
Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Nozic, D., Petrović, N., Mandušić, V.,& Krajnović, M. M. (2016). The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia.
Archives of Virology, 161(5), 1189-1198.
https://doi.org/10.1007/s00705-016-2777-z
Jovanović-Ćupić SP, Glišić S, Stanojevic M, Nozic D, Petrović N, Mandušić V, Krajnović MM. The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. Archives of Virology. 2016;161(5):1189-1198
Jovanović-Ćupić Snežana P., Glišić Sanja, Stanojevic Maja, Nozic Darko, Petrović Nina, Mandušić Vesna, Krajnović Milena M., "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia" Archives of Virology, 161, no. 5 (2016):1189-1198,
https://doi.org/10.1007/s00705-016-2777-z .
1
1

In silico analysis suggests interaction between Ebola virus and the extracellular matrix

Veljković, Veljko; Glišić, Sanja; Muller, Claude P.; Scotch, Matthew; Branch, Donald R.; Perović, Vladimir R.; Senćanski, Milan V.; Veljković, Nevena V.; Colombatti, Alfonso

(2015)

TY  - JOUR
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Muller, Claude P.
AU  - Scotch, Matthew
AU  - Branch, Donald R.
AU  - Perović, Vladimir R.
AU  - Senćanski, Milan V.
AU  - Veljković, Nevena V.
AU  - Colombatti, Alfonso
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/423
AB  - The worst Ebola virus (EV) outbreak in history has hit Liberia, Sierra Leone and Guinea hardest and the trend lines in this crisis are grave, and now represents a global public health threat concern. Limited therapeutic and/or prophylactic options are available for people suffering from Ebola virus disease (EVD) and further complicate the situation. Previous studies suggested that the EV glycoprotein (GP) is the main determinant causing structural damage of endothelial cells that triggers the hemorrhagic diathesis, but molecular mechanisms underlying this phenomenon remains elusive. Using the informational spectrum method (ISM), a virtual spectroscopy method for analysis of the protein-protein interactions, the interaction of GP with endothelial extracellular matrix (ECM) was investigated. Presented results of this in silico study suggest that Elastin Microfibril Interface Located Proteins (EMILINs) are involved in interaction between GP and ECM. This finding could contribute to a better understanding of EV/endothelium interaction and its role in pathogenesis, prevention and therapy of EVD.
T2  - Frontiers in Microbiology
T1  - In silico analysis suggests interaction between Ebola virus and the extracellular matrix
VL  - 6
DO  - 10.3389/fmicb.2015.00135
ER  - 
@article{
author = "Veljković, Veljko and Glišić, Sanja and Muller, Claude P. and Scotch, Matthew and Branch, Donald R. and Perović, Vladimir R. and Senćanski, Milan V. and Veljković, Nevena V. and Colombatti, Alfonso",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/423",
abstract = "The worst Ebola virus (EV) outbreak in history has hit Liberia, Sierra Leone and Guinea hardest and the trend lines in this crisis are grave, and now represents a global public health threat concern. Limited therapeutic and/or prophylactic options are available for people suffering from Ebola virus disease (EVD) and further complicate the situation. Previous studies suggested that the EV glycoprotein (GP) is the main determinant causing structural damage of endothelial cells that triggers the hemorrhagic diathesis, but molecular mechanisms underlying this phenomenon remains elusive. Using the informational spectrum method (ISM), a virtual spectroscopy method for analysis of the protein-protein interactions, the interaction of GP with endothelial extracellular matrix (ECM) was investigated. Presented results of this in silico study suggest that Elastin Microfibril Interface Located Proteins (EMILINs) are involved in interaction between GP and ECM. This finding could contribute to a better understanding of EV/endothelium interaction and its role in pathogenesis, prevention and therapy of EVD.",
journal = "Frontiers in Microbiology",
title = "In silico analysis suggests interaction between Ebola virus and the extracellular matrix",
volume = "6",
doi = "10.3389/fmicb.2015.00135"
}
Veljković, V., Glišić, S., Muller, C. P., Scotch, M., Branch, D. R., Perović, V. R., Senćanski, M. V., Veljković, N. V.,& Colombatti, A. (2015). In silico analysis suggests interaction between Ebola virus and the extracellular matrix.
Frontiers in Microbiology, 6.
https://doi.org/10.3389/fmicb.2015.00135
Veljković V, Glišić S, Muller CP, Scotch M, Branch DR, Perović VR, Senćanski MV, Veljković NV, Colombatti A. In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Frontiers in Microbiology. 2015;6
Veljković Veljko, Glišić Sanja, Muller Claude P., Scotch Matthew, Branch Donald R., Perović Vladimir R., Senćanski Milan V., Veljković Nevena V., Colombatti Alfonso, "In silico analysis suggests interaction between Ebola virus and the extracellular matrix" Frontiers in Microbiology, 6 (2015),
https://doi.org/10.3389/fmicb.2015.00135 .
2
19
7
11

Natural Products as Promising Therapeutics for Treatment of Influenza Disease

Senćanski, Milan V.; Radosevic, Draginja; Perović, Vladimir R.; Gemović, Branislava S.; Stanojevic, Maja; Veljković, Nevena V.; Glišić, Sanja

(2015)

TY  - JOUR
AU  - Senćanski, Milan V.
AU  - Radosevic, Draginja
AU  - Perović, Vladimir R.
AU  - Gemović, Branislava S.
AU  - Stanojevic, Maja
AU  - Veljković, Nevena V.
AU  - Glišić, Sanja
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/806
AB  - The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
T2  - Current Pharmaceutical Design
T1  - Natural Products as Promising Therapeutics for Treatment of Influenza Disease
VL  - 21
IS  - 38
SP  - 5573
EP  - 5588
DO  - 10.2174/1381612821666151002113426
ER  - 
@article{
author = "Senćanski, Milan V. and Radosevic, Draginja and Perović, Vladimir R. and Gemović, Branislava S. and Stanojevic, Maja and Veljković, Nevena V. and Glišić, Sanja",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/806",
abstract = "The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.",
journal = "Current Pharmaceutical Design",
title = "Natural Products as Promising Therapeutics for Treatment of Influenza Disease",
volume = "21",
number = "38",
pages = "5573-5588",
doi = "10.2174/1381612821666151002113426"
}
Senćanski, M. V., Radosevic, D., Perović, V. R., Gemović, B. S., Stanojevic, M., Veljković, N. V.,& Glišić, S. (2015). Natural Products as Promising Therapeutics for Treatment of Influenza Disease.
Current Pharmaceutical Design, 21(38), 5573-5588.
https://doi.org/10.2174/1381612821666151002113426
Senćanski MV, Radosevic D, Perović VR, Gemović BS, Stanojevic M, Veljković NV, Glišić S. Natural Products as Promising Therapeutics for Treatment of Influenza Disease. Current Pharmaceutical Design. 2015;21(38):5573-5588
Senćanski Milan V., Radosevic Draginja, Perović Vladimir R., Gemović Branislava S., Stanojevic Maja, Veljković Nevena V., Glišić Sanja, "Natural Products as Promising Therapeutics for Treatment of Influenza Disease" Current Pharmaceutical Design, 21, no. 38 (2015):5573-5588,
https://doi.org/10.2174/1381612821666151002113426 .
15
15
19

Improving attrition rates in Ebola virus drug discovery

Glišić, Sanja; Paessler, Slobodan; Veljković, Nevena V.; Perović, Vladimir R.; Prljić, Jelena; Veljković, Veljko

(2015)

TY  - JOUR
AU  - Glišić, Sanja
AU  - Paessler, Slobodan
AU  - Veljković, Nevena V.
AU  - Perović, Vladimir R.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/709
AB  - Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in sllico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.
T2  - Expert Opinion on Drug Discovery
T1  - Improving attrition rates in Ebola virus drug discovery
VL  - 10
IS  - 9
SP  - 1025
EP  - 1032
DO  - 10.1517/17460441.2015.1062872
ER  - 
@article{
author = "Glišić, Sanja and Paessler, Slobodan and Veljković, Nevena V. and Perović, Vladimir R. and Prljić, Jelena and Veljković, Veljko",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/709",
abstract = "Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in sllico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.",
journal = "Expert Opinion on Drug Discovery",
title = "Improving attrition rates in Ebola virus drug discovery",
volume = "10",
number = "9",
pages = "1025-1032",
doi = "10.1517/17460441.2015.1062872"
}
Glišić, S., Paessler, S., Veljković, N. V., Perović, V. R., Prljić, J.,& Veljković, V. (2015). Improving attrition rates in Ebola virus drug discovery.
Expert Opinion on Drug Discovery, 10(9), 1025-1032.
https://doi.org/10.1517/17460441.2015.1062872
Glišić S, Paessler S, Veljković NV, Perović VR, Prljić J, Veljković V. Improving attrition rates in Ebola virus drug discovery. Expert Opinion on Drug Discovery. 2015;10(9):1025-1032
Glišić Sanja, Paessler Slobodan, Veljković Nevena V., Perović Vladimir R., Prljić Jelena, Veljković Veljko, "Improving attrition rates in Ebola virus drug discovery" Expert Opinion on Drug Discovery, 10, no. 9 (2015):1025-1032,
https://doi.org/10.1517/17460441.2015.1062872 .
2
3
4
5

Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic

Veljković, Veljko; Paessler, Slobodan; Glišić, Sanja; Prljić, Jelena; Perović, Vladimir R.; Veljković, Nevena V.; Scotch, Matthew

(2015)

TY  - JOUR
AU  - Veljković, Veljko
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Scotch, Matthew
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/863
AB  - A key factor in the effectiveness of the seasonal influenza vaccine is its immunological compatibility with the circulating viruses during the season. Here we propose a new bioinformatics approach for analysis of influenza viruses which could be used as an efficient tool for selection of vaccine viruses, assessment of the effectiveness of seasonal influenza vaccines, and prediction of the epidemic/pandemic potential of novel influenza viruses.
T2  - Frontiers in Microbiology
T1  - Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic
VL  - 6
DO  - 10.3389/fmicb.2015.01456
ER  - 
@article{
author = "Veljković, Veljko and Paessler, Slobodan and Glišić, Sanja and Prljić, Jelena and Perović, Vladimir R. and Veljković, Nevena V. and Scotch, Matthew",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/863",
abstract = "A key factor in the effectiveness of the seasonal influenza vaccine is its immunological compatibility with the circulating viruses during the season. Here we propose a new bioinformatics approach for analysis of influenza viruses which could be used as an efficient tool for selection of vaccine viruses, assessment of the effectiveness of seasonal influenza vaccines, and prediction of the epidemic/pandemic potential of novel influenza viruses.",
journal = "Frontiers in Microbiology",
title = "Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic",
volume = "6",
doi = "10.3389/fmicb.2015.01456"
}
Veljković, V., Paessler, S., Glišić, S., Prljić, J., Perović, V. R., Veljković, N. V.,& Scotch, M. (2015). Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic.
Frontiers in Microbiology, 6.
https://doi.org/10.3389/fmicb.2015.01456
Veljković V, Paessler S, Glišić S, Prljić J, Perović VR, Veljković NV, Scotch M. Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. Frontiers in Microbiology. 2015;6
Veljković Veljko, Paessler Slobodan, Glišić Sanja, Prljić Jelena, Perović Vladimir R., Veljković Nevena V., Scotch Matthew, "Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic" Frontiers in Microbiology, 6 (2015),
https://doi.org/10.3389/fmicb.2015.01456 .
14
11
6
9

Preclinical discovery and development of maraviroc for the treatment of HIV

Veljković, Nevena V.; Vucicevic, Jelica; Tassini, Sabrina; Glišić, Sanja; Veljković, Veljko; Radi, Marco

(2015)

TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Vucicevic, Jelica
AU  - Tassini, Sabrina
AU  - Glišić, Sanja
AU  - Veljković, Veljko
AU  - Radi, Marco
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/558
AB  - Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.
T2  - Expert Opinion on Drug Discovery
T1  - Preclinical discovery and development of maraviroc for the treatment of HIV
VL  - 10
IS  - 6
SP  - 671
EP  - 684
DO  - 10.1517/17460441.2015.1041497
ER  - 
@article{
author = "Veljković, Nevena V. and Vucicevic, Jelica and Tassini, Sabrina and Glišić, Sanja and Veljković, Veljko and Radi, Marco",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/558",
abstract = "Introduction: Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1. Areas covered: This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data. Expert opinion: The profound understanding of HIVs entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.",
journal = "Expert Opinion on Drug Discovery",
title = "Preclinical discovery and development of maraviroc for the treatment of HIV",
volume = "10",
number = "6",
pages = "671-684",
doi = "10.1517/17460441.2015.1041497"
}
Veljković, N. V., Vucicevic, J., Tassini, S., Glišić, S., Veljković, V.,& Radi, M. (2015). Preclinical discovery and development of maraviroc for the treatment of HIV.
Expert Opinion on Drug Discovery, 10(6), 671-684.
https://doi.org/10.1517/17460441.2015.1041497
Veljković NV, Vucicevic J, Tassini S, Glišić S, Veljković V, Radi M. Preclinical discovery and development of maraviroc for the treatment of HIV. Expert Opinion on Drug Discovery. 2015;10(6):671-684
Veljković Nevena V., Vucicevic Jelica, Tassini Sabrina, Glišić Sanja, Veljković Veljko, Radi Marco, "Preclinical discovery and development of maraviroc for the treatment of HIV" Expert Opinion on Drug Discovery, 10, no. 6 (2015):671-684,
https://doi.org/10.1517/17460441.2015.1041497 .
1
7
6
6

Demonstration of a Direct Interaction between beta(2)-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics

Mandic, Maja; Drinovec, Luka; Glišić, Sanja; Veljković, Nevena V.; Nohr, Jane; Vrecl, Milka

(2014)

TY  - JOUR
AU  - Mandic, Maja
AU  - Drinovec, Luka
AU  - Glišić, Sanja
AU  - Veljković, Nevena V.
AU  - Nohr, Jane
AU  - Vrecl, Milka
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/216
AB  - Glucose metabolism is under the cooperative regulation of both insulin receptor (IR) and beta(2)-adrenergic receptor (beta(2)AR), which represent the receptor tyrosine kinases (RTKs) and seven transmembrane receptors (7TMRs), respectively. Studies demonstrating cross-talk between these two receptors and their endogenous coexpression have suggested their possible interactions. To evaluate the effect of IR and prospective heteromerization on beta(2)AR properties, we showed that IR coexpression had no effect on the ligand binding properties of beta(2)AR; however, IR reduced beta(2)AR surface expression and accelerated its internalization. Additionally, both receptors displayed a similar distribution pattern with a high degree of colocalization. To test the possible direct interaction between beta(2)AR and IR, we employed quantitative BRET 2 saturation and competition assays. Saturation assay data suggested constitutive beta(2)AR and IR homo-and heteromerization. Calculated acceptor/donor (AD(50)) values as a measure of the relative affinity for homo-and heteromer formation differed among the heteromers that could not be explained by a simple dimer model. In heterologous competition assays, a transient increase in the BRET2 signal with a subsequent hyperbolical decrease was observed, suggesting higher-order heteromer formation. To complement the BRET2 data, we employed the informational spectrum method (ISM), a virtual spectroscopy method to investigate protein-protein interactions. Computational peptide scanning of beta(2)AR and IR identified intracellular domains encompassing residues at the end of the 7th TM domain and C-terminal tail of beta(2)AR and a cytoplasmic part of the IR beta chain as prospective interaction domains. ISM further suggested a high probability of heteromer formation and homodimers as basic units engaged in heteromerization. In summary, our data suggest direct interaction and higher-order beta(2)AR: IR oligomer formation, likely comprising heteromers of homodimers.
T2  - PLOS One
T1  - Demonstration of a Direct Interaction between beta(2)-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics
VL  - 9
IS  - 11
DO  - 10.1371/journal.pone.0112664
ER  - 
@article{
author = "Mandic, Maja and Drinovec, Luka and Glišić, Sanja and Veljković, Nevena V. and Nohr, Jane and Vrecl, Milka",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/216",
abstract = "Glucose metabolism is under the cooperative regulation of both insulin receptor (IR) and beta(2)-adrenergic receptor (beta(2)AR), which represent the receptor tyrosine kinases (RTKs) and seven transmembrane receptors (7TMRs), respectively. Studies demonstrating cross-talk between these two receptors and their endogenous coexpression have suggested their possible interactions. To evaluate the effect of IR and prospective heteromerization on beta(2)AR properties, we showed that IR coexpression had no effect on the ligand binding properties of beta(2)AR; however, IR reduced beta(2)AR surface expression and accelerated its internalization. Additionally, both receptors displayed a similar distribution pattern with a high degree of colocalization. To test the possible direct interaction between beta(2)AR and IR, we employed quantitative BRET 2 saturation and competition assays. Saturation assay data suggested constitutive beta(2)AR and IR homo-and heteromerization. Calculated acceptor/donor (AD(50)) values as a measure of the relative affinity for homo-and heteromer formation differed among the heteromers that could not be explained by a simple dimer model. In heterologous competition assays, a transient increase in the BRET2 signal with a subsequent hyperbolical decrease was observed, suggesting higher-order heteromer formation. To complement the BRET2 data, we employed the informational spectrum method (ISM), a virtual spectroscopy method to investigate protein-protein interactions. Computational peptide scanning of beta(2)AR and IR identified intracellular domains encompassing residues at the end of the 7th TM domain and C-terminal tail of beta(2)AR and a cytoplasmic part of the IR beta chain as prospective interaction domains. ISM further suggested a high probability of heteromer formation and homodimers as basic units engaged in heteromerization. In summary, our data suggest direct interaction and higher-order beta(2)AR: IR oligomer formation, likely comprising heteromers of homodimers.",
journal = "PLOS One",
title = "Demonstration of a Direct Interaction between beta(2)-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics",
volume = "9",
number = "11",
doi = "10.1371/journal.pone.0112664"
}
Mandic, M., Drinovec, L., Glišić, S., Veljković, N. V., Nohr, J.,& Vrecl, M. (2014). Demonstration of a Direct Interaction between beta(2)-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics.
PLOS One, 9(11).
https://doi.org/10.1371/journal.pone.0112664
Mandic M, Drinovec L, Glišić S, Veljković NV, Nohr J, Vrecl M. Demonstration of a Direct Interaction between beta(2)-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics. PLOS One. 2014;9(11)
Mandic Maja, Drinovec Luka, Glišić Sanja, Veljković Nevena V., Nohr Jane, Vrecl Milka, "Demonstration of a Direct Interaction between beta(2)-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics" PLOS One, 9, no. 11 (2014),
https://doi.org/10.1371/journal.pone.0112664 .
15
11
14

Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism

Veljković, Veljko; Glišić, Sanja; Veljković, Nevena V.; Bojić, Tijana; Dietrich, Ursula; Perović, Vladimir R.; Colombatti, Alfonso

(2014)

TY  - JOUR
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Veljković, Nevena V.
AU  - Bojić, Tijana
AU  - Dietrich, Ursula
AU  - Perović, Vladimir R.
AU  - Colombatti, Alfonso
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/229
AB  - Despite plausible evidence for beneficial effects of the vaccination against influenza in cardiovascular diseases (CVD) very limited studies have been carried out to explain the molecular mechanism of this phenomenon. Using the informational spectrum method (ISM), a virtual spectroscopy method for analysis of protein-protein interactions, the bradykinin 2 receptor (BKB2R) was identified as a principal host protein which could mediate molecular processes underlying the cardioprotective effect of influenza vaccines. Based on this finding we suggest that some antibodies elicited by influenza vaccines act as agonists, which activate a BKB2R-associated signaling pathway contributing to the protection against CVD. The ISM analysis of 14 influenza viruses, which were used as components of seasonal vaccines, revealed four vaccine viruses A/Beijing/262/95(H1N1), A/NewCaledonia/20/1999(H1N1), A/Christchurch/28/2003(H3N2) and A/Perth/16/2009(H3N2), which could be suited best for further studies on the cardioprotective effect of influenza vaccines. (C) 2014 Elsevier Ltd. All rights reserved.
T2  - Vaccine
T1  - Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism
VL  - 32
IS  - 48
SP  - 6569
EP  - 6575
DO  - 10.1016/j.vaccine.2014.07.007
ER  - 
@article{
author = "Veljković, Veljko and Glišić, Sanja and Veljković, Nevena V. and Bojić, Tijana and Dietrich, Ursula and Perović, Vladimir R. and Colombatti, Alfonso",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/229",
abstract = "Despite plausible evidence for beneficial effects of the vaccination against influenza in cardiovascular diseases (CVD) very limited studies have been carried out to explain the molecular mechanism of this phenomenon. Using the informational spectrum method (ISM), a virtual spectroscopy method for analysis of protein-protein interactions, the bradykinin 2 receptor (BKB2R) was identified as a principal host protein which could mediate molecular processes underlying the cardioprotective effect of influenza vaccines. Based on this finding we suggest that some antibodies elicited by influenza vaccines act as agonists, which activate a BKB2R-associated signaling pathway contributing to the protection against CVD. The ISM analysis of 14 influenza viruses, which were used as components of seasonal vaccines, revealed four vaccine viruses A/Beijing/262/95(H1N1), A/NewCaledonia/20/1999(H1N1), A/Christchurch/28/2003(H3N2) and A/Perth/16/2009(H3N2), which could be suited best for further studies on the cardioprotective effect of influenza vaccines. (C) 2014 Elsevier Ltd. All rights reserved.",
journal = "Vaccine",
title = "Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism",
volume = "32",
number = "48",
pages = "6569-6575",
doi = "10.1016/j.vaccine.2014.07.007"
}
Veljković, V., Glišić, S., Veljković, N. V., Bojić, T., Dietrich, U., Perović, V. R.,& Colombatti, A. (2014). Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism.
Vaccine, 32(48), 6569-6575.
https://doi.org/10.1016/j.vaccine.2014.07.007
Veljković V, Glišić S, Veljković NV, Bojić T, Dietrich U, Perović VR, Colombatti A. Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism. Vaccine. 2014;32(48):6569-6575
Veljković Veljko, Glišić Sanja, Veljković Nevena V., Bojić Tijana, Dietrich Ursula, Perović Vladimir R., Colombatti Alfonso, "Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism" Vaccine, 32, no. 48 (2014):6569-6575,
https://doi.org/10.1016/j.vaccine.2014.07.007 .
54
33
29
33

Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b

Jovanović-Ćupić, Snežana P.; Glišić, Sanja; Stanojevic, M.; Vasiljevic, N.; Bojić, Tijana; Božović, Ana M.; Dimitrijević, Bogomir B.

(2014)

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, M.
AU  - Vasiljevic, N.
AU  - Bojić, Tijana
AU  - Božović, Ana M.
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5858
AB  - Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.
T2  - Archives of biological sciences
T1  - Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b
VL  - 66
IS  - 1
SP  - 193
EP  - 201
DO  - 10.2298/ABS1401193J
ER  - 
@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, M. and Vasiljevic, N. and Bojić, Tijana and Božović, Ana M. and Dimitrijević, Bogomir B.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5858",
abstract = "Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.",
journal = "Archives of biological sciences",
title = "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b",
volume = "66",
number = "1",
pages = "193-201",
doi = "10.2298/ABS1401193J"
}
Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Vasiljevic, N., Bojić, T., Božović, A. M.,& Dimitrijević, B. B. (2014). Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b.
Archives of biological sciences, 66(1), 193-201.
https://doi.org/10.2298/ABS1401193J
Jovanović-Ćupić SP, Glišić S, Stanojevic M, Vasiljevic N, Bojić T, Božović AM, Dimitrijević BB. Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. Archives of biological sciences. 2014;66(1):193-201
Jovanović-Ćupić Snežana P., Glišić Sanja, Stanojevic M., Vasiljevic N., Bojić Tijana, Božović Ana M., Dimitrijević Bogomir B., "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b" Archives of biological sciences, 66, no. 1 (2014):193-201,
https://doi.org/10.2298/ABS1401193J .
2